Glioma Treatment Market (Type: Low-grade and High-grade)- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2022-2030

According to Nova one advisor, the global Glioma Treatment market size is expected to hit around USD 7.55 billion by 2030 from valued at USD 4.59 billion in 2021 and growing at a CAGR of 5.14% from 2022 to 2030.

Glioma is a condition that covers a broad category of brain and spinal cord tumors that affect the glial cells in the brain. Glioma can affect brain function and can be fatal depending on its location and severity of the tumor. Different types of gliomas are astrocytoma, brain stem gliomas, ependymomas, mixed gliomas (oligo-astrocytomas), oligodendrogliomas, and optic pathway gliomas. Common glioma symptoms include headache, nausea, vomiting, confusion, and decline in brain function. Various therapeutic options are available for the treatment of glioma. These include radiation therapy for glioma, chemotherapy, glioma targeted therapy, and surgery. Late stage clinical pipeline drugs can be effective treatment options for glioma.

Approval of late stage pipeline drug designation to certain molecules for the treatment of glioma is a major factor that is likely to drive the global glioma diagnosis and treatment market. For instance, on December 05, 2019, the U.S. FDA and European Medicines Agency granted orphan drug designation to Adastra Pharmaceuticals drug zotiraciclib, a multikinase inhibitor. This drug is being evaluated in two phase 1b clinical studies of patients with glioblastoma ? the most common glioma histology for the treatment of glioma. Rise in prevalence of brain cancer and increase in awareness regarding various types of gliomas are also fueling the global glioma treatment market. Moreover, strategic alliances for the development of glioma therapeutics products and increase in exposure of humans to radiation in the last few years, which leads to higher incidence of brain cancer, are some of the key factors propelling the global glioma therapy market.

Report Scope of the Glioma Treatment Market

COVID-19 Impact on Global Glioma Treatment Market

The outbreak of COVID-19 has had a negative effect on the global glioma treatment market. Governments of affected countries gave instructions for the postponement of non-essential surgeries and patient visits. Surgical neuro-oncology is a specialty that created a dilemma in continuing surgical care during the pandemic. Several ICU facilities, such as ventilators, personal protective equipment, and medical staff, were rerouted to COVID-19 cases, prompting the suspension of surgical neuro-oncology services during the pandemic. Instability in the provision of adequate medical care to critically-ill cancer patients was witnessed during the pandemic. Additionally, glioblastoma patients are vulnerable to the COVID-19 infection, which led to postponement of treatments and surgeries. Thus, there was a decrease in Y-o-Y growth due to postponed brain surgeries in hospitals and ambulatory surgical centers during the COVID-19 outbreak.

Rise in Incidence and Prevalence of High Grade Gliomas to Drive Market

In terms of type, the global glioma treatment market has been divided into low-grade gliomas and high-grade gliomas. High-grade gliomas is anticipated to be a highly lucrative segment in the near future due to the availability of more options for diagnosis and treatment of glioma tumor of this grade. High-grade gliomas are highly severe tumors and largely occur in children and adults. Various factors such as frequent radiation therapies, improper surgeries of the brain, and multiple therapies are expected to drive the market. Manufacturers are emphasizing on the use of innovative technologies, which is projected to fuel the segment in the near future. For instance, ASCO 2022 would get fresh clinical data on the usage of Kiyatec's ex vivo 3D cell culture technique for high-grade glioma. Furthermore, rise in prevalence and incidence of high-grade gliomas is driving the market. High-grade glioma is one of the frequently diagnosed primary brain tumors. According to the National Library of Medicine, the incidence rate of high-grade glioma is about 5.8 males and 4.1 females per 100,000 people per year.

Surgery, the First Step in Treatment of Most Gliomas

Based on treatment, the surgery segment dominated the global glioma treatment market in 2021. This trend is projected to continue during the forecast period. Surgery to remove as many tumors as possible is usually the first step in treating most gliomas. In some cases, gliomas are small and can be easily removed from the surrounding healthy brain tissue, allowing for complete surgical removal. Moreover, presence of reimbursement policies that encourage healthcare providers to maintain quality infrastructure is expected to boost the surgery segment. Thus, increase in success rate of surgeries and reimbursement policies is expected to drive the surgery segment. Additionally, rise in number of surgical procedures for the treatment of glioma in growing economies, including China and India, is boosting the segment. Governments of China and India have increased their healthcare spend, which in turn is augmenting the admission of patients in hospitals.

Regional Outlook of Global Glioma Treatment Market

In terms of region, North America dominated the global glioma treatment market in 2021. This can be ascribed to the rise in approval of new products for glioma treatment, higher prevalence of brain tumor cases, growing exposure of population to radiation, and presence of major companies in the region. For instance, according to stats by the American Society of Clinical Oncology (ASCO), an estimated 23,820 adults in the U.S. were diagnosed with primary cancerous tumors of the brain and spinal cord in 2018. Brain tumors accounted for 85% to 90% of all primary CNS tumors.

The market in Asia Pacific is expected to be highly lucrative during the forecast period due to the launch of approved products in the region in the latter half of the forecast period, higher geriatric population, increase in number of patients with cancer, and rise in awareness regarding diseases & treatment.

Key Developments in Global Glioma Treatment Market

• In June 2022, Novartis, a leading biopharmaceutical company, announced that ‘Tafinlar’ and Mekinist significantly improved the efficacy in patients aged 1 to 17 years with BRAF V600 pediartric low-grade glioma, which is the first systematic treatment as compared to chemotherapy
• In June 2022, VBI Vaccine, a renowned biopharmaceutical company, received U.S. FDA Orphan Drug Designation for ‘VBI-1901’ for the treatment of glioblastoma
• In May 2022, according to the study published by BMC cancer, the University of Surrey showed that a chain of amino acids is effective in targeting and inhibiting the function of a family of genes responsible for the growth of Glioblastoma Multiforme (GBM)
• In April 2022, CNS Pharmaceuticals announced plans to commence the pivotal trial of ‘Berubin’ to treat recurrent GBM
• On February 10, 2022, Theragnostics announced that its novel radio therapeutic I-123 PARPi therapeutic agent for the treatment of GBM had been awarded the U.K.'s Medicines & Healthcare Products Regulatory Agency approval for the treatment of primary & recurrent glioblastoma multiforme
• In January 2022, ITM Isotope Technologies Munich SE, a Germany-based pharmaceutical company, entered into a cooperation agreement with Helmholtz Zentrum München, the German Research Center for Environmental Health, for the clinical development of radiopharmaceutical therapy to treat GBM
• In December 2021, ICAD Technology announced that the first recurrent glioblastoma tumor was treated with Xoft Brain IORT in the U.S.
• In October 2021, the FDA granted a breakthrough designation to Alpha Tau’s device ‘Alpha DaRT’ for the treatment of GBM

Some of the prominent players in the Glioma Treatment Market include:

• Sun Pharmaceutical Industries Ltd.
• Amgen, Inc.
• Teva Pharmaceutical Industries Ltd
• Bristol-Myers Squibb Company
• Pfizer, Inc.
• Merck KGaA
• F. Hoffmann-La Roche Ltd

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Glioma Treatment market

• Type
• Low-grade
• grade I
• grade II
• High-grade
• grade III
• grade IV
• Treatment
• Surgery
• Radiation Therapy
• Chemotherapy
• Targeted Drug Therapy
• Others

By Geography

North America

• U.S.
• Canada

Europe

• Germany
• France
• United Kingdom
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Southeast Asia
• Rest of Asia Pacific

Latin America

• Brazil
• Rest of Latin America

Middle East & Africa (MEA)

• GCC
• North Africa
• South Africa
• Rest of Middle East & Africa

Key Benefits for Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the global Glioma Treatment industry analysis from 2022 to 2030 to identify the prevailing Glioma Treatment industry opportunity.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the global Glioma Treatment industry segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global Glioma Treatment industry trends, key players, market segments, application areas, and market growth strategies.